Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT EBITDA Margin

EBITDA as a percentage of revenue.

Veracyte, Inc.NASDAQ: VCYT

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 16.2%

EBITDA Margin was 16.2% in Q2 FY2026, up 11.0 pp from a year earlier. On a trailing-twelve-month basis it was 23.1%, up 13.6 pp year over year. Over 3 fiscal years it widened by 20.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 36.5% for the fiscal year ending Dec 2026, up from 17.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
16.2%-9.3 pp QoQ
Last fiscal yearDec 2025
17.3%+6.3 pp YoY
LTMJun 2026
23.1%+13.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+11.0 pp+15.0 pp+4.0 pp
1 year+6.3 pp+19.1 pp+12.8 pp
3 years+20.8 pp+13.2 pp-7.6 pp
5 years+8.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
17.3%
Year-over-year change
+6.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 EBITDA Margin of 23.1% is the highest of the 10 companies compared; the peer median is -19.1%.
  • Its year-over-year change of +13.6 pp is the 3rd highest of 10, against a peer median of -12.0 pp.
  • Over three fiscal years its change of +20.8 pp compares with a peer median of +98.7 pp.
VCYT Competitors Peer median
EBITDA Margin for VCYT and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202623.1% +13.6 pp+20.8 pp
BLLNBillionToOne, Inc.LTM Jun 202612.6% +21.8 pp—
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
CSTLCastle Biosciences, Inc.LTM Mar 2026-0.2% -12.0 pp+45.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-16.8% -24.5 pp+171.2 pp
BDSXBiodesix, Inc.LTM Mar 2026-19.1% +17.8 pp+110.1 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2329.5% -862.2 pp+207.6 pp
Peer median (excluding VCYT) -19.1%-12.0 pp+98.7 pp

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.51M296.54M361.05M445.76M517.15M
Cost of Revenue74.4M101.58M112.9M147.62M157.1M
Gross Profit145.11M194.95M248.15M298.15M360.05M
Gross Margin66.1%65.7%68.7%66.9%69.6%
Research & Development29.84M40.6M57.31M69.29M70.81M
Selling, General & Admin181.19M174.08M184.23M206.04M210.95M
Operating Expenses227.02M236.04M333.94M282M285.9M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
EBITDA(61.82M)(10.3M)(49.41M)49.21M89.62M
EBITDA Margin-28.2%-3.5%-13.7%11.0%17.3%
Operating Income(81.9M)(41.08M)(85.8M)16.14M74.15M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Income135K1.97M7.34M11.15M0
Interest Expense241K198K15K2K0
Other Income / Expenses254K4.65M9.18M9.6M(5.95M)
Income Before Tax(81.65M)(36.43M)(76.61M)25.74M68.2M
Pre-Tax Margin-37.2%-12.3%-21.2%5.8%13.2%
Income Tax Expense(6.09M)133K(2.21M)1.61M1.85M
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Basic)(1.11)(0.51)(1.02)0.320.84
EPS (Diluted)(1.11)(0.51)(1.02)0.310.82
Weighted Avg Shares67.89M71.55M72.64M76.48M78.58M
Weighted Avg Shares (Diluted)67.89M71.55M72.64M78.16M80.57M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.